Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

NCT06694740

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Assistance Publique - Hôpitaux de Paris
Enrollment	170 participants

Key Eligibility Criteria

Inclusion (6)

- Patient e 18 years old
- SOFA score for first 24 hours post-admission e 6
- Mechanically ventilated at the time of inclusion (non-invasive ventilation (NIV) and high-flow nasal oxygen excluded)
- mHLA-DR\< 8,000 AB/C measured between the 5th and 10th day after admission to the intensive care unit
- Patient affiliated to a social security scheme

... and 1 more (see full listing online)

Exclusion (10)

- Patient with estimated life expectancy of less than 3 months
- Patients with a predicted remaining stay in intensive care \< 72 hours
- Patient with pre-existing immunosuppression: solid cancer active or in remission for \< 5 years, active hemopathy or in remission for \< 5 years, systemic disease (including in the absence of specific treatment), solid organ transplant or marrow allograft patient, patient suffering from a HIV infection
- Patients with an expected prolonged duration of mechanical ventilation: comatose or vegetative patients (admission for severe stroke with Glasgow score \< 8, patient resuscitated from an arterial stroke,) patients with tracheotomy for ENT problems, patients suffering from muscular disease (e.g. myopathy), patients on long-term mechanical ventilation
- Pregnant or breast-feeding women

... and 5 more (see full listing online)

Locations (2 total)

Dr de Roquetaillade, Paris, France
Pr Dépret, Paris, France